Related Experiment Video

Updated: May 3, 2026

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

11.1K

Fine-tuning the effects of T-cell therapy

    Cancer Discovery
    |February 7, 2014
    PubMed

    Insights

    Researchers developed inhibitory chimeric antigen receptors to protect normal tissues from T-cell therapy damage. These engineered molecules divert harmful off-target responses, enhancing treatment safety.

    Area of Science:

    • Immunology
    • Molecular Engineering
    • Oncology

    Background:

    • Engineered T-cell therapies show promise but can cause off-target toxicities.
    • Protecting healthy tissues during T-cell immunotherapy is a critical challenge.

    Discussion:

    • Inhibitory chimeric antigen receptors (ICARs) are engineered molecules designed to mitigate T-cell therapy side effects.
    • ICARs function by redirecting T-cell activity away from unintended targets, thereby reducing damage to normal tissues.

    Key Insights:

    • Development of ICARs offers a novel strategy to improve the safety profile of T-cell-based treatments.
    • This engineering approach enhances the therapeutic window for T-cell therapies by minimizing collateral damage.

    Outlook:

    • Further research into ICARs could lead to safer and more effective T-cell immunotherapies.
    • ICARs represent a significant advancement in managing on-target, off-tumor effects in cancer treatment.

    More Related Videos

    Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

    Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

    Published on: January 14, 2011

    14.1K
    Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

    Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

    Published on: May 6, 2019

    8.2K

    Related Concept Videos

    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    2.5K
    T Cell Activation and Clonal Selection01:22

    T Cell Activation and Clonal Selection

    T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
    Naive T cells that have not yet encountered an antigen express two primary CD...
    13.7K